"東京は千駄木にある日本医科大学付属病院のケロイド外来（形成外科・再建外科・美容外科が行っている専門外来）には、毎年1年間で2000人弱のケロイドの新患患者様が日本全国からおみえになりますが、年に1-2回しか来れない遠方の方や海外にお住まいの方でも無理なく治療を継続できるような治療プランを提案させていただいております。現在ではケロイドは完治できる疾患となりました。"

During the past decade, Nippon Medical School Hospital conducted 67 clinical trials. In the 10-year time frame, 67 clinical trials started and 38 clinical trials were completed, i.e. on average, 56.7% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 29 clinical trials were completed. i.e. 126.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nippon Medical School Hospital" #1 sponsor was "Boehringer Ingelheim" with 11 trials, followed by "Hoffmann-La Roche" with 6 trials sponsored, "Merck Sharp & Dohme LLC" with 5 trials sponsored, "Eli Lilly and Company" with 4 trials sponsored and "Pfizer" with 4 trials sponsored. Other sponsors include 43 different institutions and companies that sponsored additional 38 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nippon Medical School Hospital" #1 collaborator was "Eisai Inc." with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Incyte Corporation" with 2 trials as a collaborator, "Japan Lung Cancer Society" with 2 trials as a collaborator and "Maruishi Pharmaceutical" with 2 trials as a collaborator. Other collaborators include 12 different institutions and companies that were collaborators in the rest 21 trials.

According to Clinical.Site data, the most researched conditions in "Nippon Medical School Hospital" are "Atrial Fibrillation" (5 trials), "Prostatic Neoplasms" (5 trials), "Idiopathic Pulmonary Fibrosis" (3 trials), "Atopic Dermatitis" (2 trials) and "Carcinoma, Renal Cell" (2 trials). Many other conditions were trialed in "Nippon Medical School Hospital" in a lesser frequency.

Most popular intervention types in "Nippon Medical School Hospital" are "Drug" (69 trials), "Other" (7 trials), "Biological" (6 trials), "Device" (4 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (26 trials), "Pembrolizumab" (6 trials), "Enzalutamide" (5 trials), "Nintedanib" (5 trials) and "placebo" (4 trials). Other intervention names were less common.

The vast majority of trials in "Nippon Medical School Hospital" are 68 trials for "All" genders, 9 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Nippon Medical School Hospital". undefined are not yet recruiting, 13 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 43 completed trials in Nippon Medical School Hospital, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Nippon Medical School Hospital, 2 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 49 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 2 trials that are defined as “Not Applicable".